SCHEMBL6283590

SCHEMBL6283590

CC(C)(C)OC(=O)CN1C(=O)NCC1CC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 2/20 0.38
PLA2G5 P39877 2/20 0.38
IDO1 P14902 1/20 0.35
TSHR P16473 1/20 0.33
ITGB1 P05556 2/20 0.33
ITGA5 P08648 2/20 0.33
ITGB3 P05106 1/20 0.33
ITGB2 P05107 1/20 0.33
ITGAV P06756 1/20 0.33
ITGA2B P08514 1/20 0.33
ITGB5 P18084 1/20 0.33
ITGAL P20701 1/20 0.33
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.31
RAMP1 O60894 3/20 0.31
CALCRL Q16602 3/20 0.31
DDB1 Q16531 1/20 0.30
CRBN Q96SW2 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282333 0.92 PLA2G10 (0.40) PLA2G10PLA2G5KDM4EALDH1A1POLB
SCHEMBL6283003 0.76 PLA2G10 (0.42) PLA2G10PLA2G5ALDH1A1SMN1; SMN2
SCHEMBL14749821 0.67 TSHR (0.36) TSHRALDH1A1
SCHEMBL9086652 0.67 PLA2G10 (0.37) PLA2G10PLA2G5ALDH1A1RAMP1CALCRL
SCHEMBL9090424 0.67 PLA2G10 (0.37) PLA2G10PLA2G5ALDH1A1RAMP1CALCRL
SCHEMBL6283964 0.67 ITGB1 (0.44) TSHRITGB1ITGA5ALDH1A1POLB
SCHEMBL8712263 0.66 PLA2G10 (0.37) PLA2G10PLA2G5KDM4EALDH1A1
SCHEMBL17951050 0.66 PLA2G10 (0.42) PLA2G10PLA2G5KDM4EALDH1A1POLB
SCHEMBL18204610 0.66 PLA2G10 (0.42) PLA2G10PLA2G5KDM4EALDH1A1POLB
SCHEMBL24709213 0.65 HTR4 (0.41) PLA2G10PLA2G5ITGB3ITGA2BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852744-B2 Pyrrolidine derivatives and their use as chymase inhibitor DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2005-02-08 US disclosed
US-20040102384-A1 Pyrrolidine derivatives and their use as chymase inhibitor DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-05-27 US disclosed
EP-1313730-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR Dainippon Pharmaceutical Co., Ltd. (JP) 2003-05-28 EP disclosed
WO-2002018378-A1 PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102384-A1 Pyrrolidine derivatives and their use as chymase inhibitor CMA1, CTRL, TPSD1 PLA2G10 4224/4885PLA2G5 3701/4885IDO1 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.